Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Boele Florien W, Frances Sé M, Darlix Amélie, Ducray Francois, Cartalat Stéphanie, Guerdoux Estelle, Tabouret Emeline, Burger Michael C, Rydén Isabelle, Malmstrom Annika, Vauleon Elodie, Kazda Tomas, Renovanz Mirjam, Werner Jan-Michael, Welsh Liam, Sanghera Paul, Dehais Caroline, Desideri Isacco, McBain Catherine, Mehta Shaveta, Lord Hannah, Jena Rajesh, Foweraker Karen, Ashkan Keyoumars, Engelhardt Julien, Bourg Veronique, Herrlinger Ulrich, Lawson McLean Aaron, Hertler Caroline, Haldbo-Classen Lene, Dahlrot Rikke H, Noel Georges, Durando Xavier, Hrab Ioana, Razis Evangelia, Weller Michael, Muhic Aida, Klein Martin
Аннотация
METHODS: In this cross-sectional observational study, patients with oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q-codeleted, diagnosed ≥ 5 years ago, were recruited. Patients completed patient-reported outcome measures (EORTC QLQ-C30; BN20; MOS Cognitive Complaints Scale) and cognitive tests (HVLT-R, TMT, COWAT). Associations between HRQOL and cognition outcomes, and clinical variables (time since diagnosis; age at diagnosis; progression; tumor location; treatments delivered; time since treatment; current medication) were explored with regression analyses.
RESULTS: In total, 237 patients M = 9.9 years postdiagnosis (SD = 4.2, range 5.0-25.8) took part from 33 sites across 9 countries. Clinically relevant levels of impairment were noted in >40% of patients on EORTC QLQ-C30 scales for cognitive functioning (56.1%), emotional functioning (49.8%), fatigue (45.1%), and physical functioning (40.5%). In individuals, cognitive impairment ranged from 17.7% for processing speed to 46.0% for episodic verbal memory (delayed recall). Among other clinical factors such as current use of antiseizure medication or antidepressants, age, disease progression, time since diagnosis and time since treatment, and radiotherapy treatment (ever received) was linked to HRQOL and cognitive functioning outcomes (posthoc analyses for cumulative radiotherapy dose: not significant).
CONCLUSIONS: In oligodendroglioma survivors, HRQOL and cognitive impairment are prevalent even years into follow-up. Supportive care and rehabilitation should be prioritized to mitigate these challenges and improve daily functioning.
TRIAL REGISTRATION: NCT04708548.